Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

GSK. The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing. Influenza causes 140,000 to ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

influenza, malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily.

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health ...